Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving low-dose dasatinib therapy

Ontogeny, aging, and gender-related changes in hepatic multidrug resistant protein genes in rats

(2017) Qiong-Ni Zhu et al.   LIFE SCIENCES

Efficacy of intermittently administered dasatinib with a reduced dose in an elderly patient with chronic myeloid leukemia

(2016) Masahiro Imamura   Geriatrics & Gerontology International

Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia

(2015) Yoji Ishida et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

HPLC–MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)

(2011) Antonio D’Avolio et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

“Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia

(2010) Roberto Latagliata et al.   LEUKEMIA RESEARCH

Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders

(2009) N. Singh et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

(2008) Neil P. Shah et al.   CANCER CELL